Enzymatic assessment of paraoxonase 1 activity on HDL subclasses: A practical zymogram method to assess HDL function

Clinica Chimica Acta

Volumn 415, Issue , 2013, Pages 162-168

  Gugliucci, Alejandro ^a   Caccavello, Russell ^a   Kotani, Kazuhiko ^a,b,c   Sakane, Naoki ^c   Kimura, Satoshi ^d  

^a TOURO UNIVERSITY CALIFORNIA   (United States)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^d SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

Author keywords

Arylesterase; Cardiovascular risk; HDL composition; High density lipoprotein subclasses; Optical densitometry analysis; PON1

Indexed keywords

4 AMINOPHENAZONE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHENOL; PHENYLACETIC ACID; POLYACRYLAMIDE GEL;

ADULT; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME KINETICS; FEMALE; FREEZE THAWING; GEL ELECTROPHORESIS; HUMAN; HYDROLYSIS; LINEAR SYSTEM; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; REPRODUCIBILITY; RISK ASSESSMENT; ZYMOGRAPHY;

ADULT; AMPYRONE; ARYLDIALKYLPHOSPHATASE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME ASSAYS; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PHENOL; PHENYLACETATES;

EID: 84869102186     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.10.044     Document Type: Article

References (47)

1. Mackness M.I., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991, 286:152-154.
2. Shih D.M., Gu L., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
3. Shih D.M., Lusis A.J. The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr Opin Lipidol 2009, 20:288-292.
4. Camps J., Marsillach J., Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009, 46:83-106.
5. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., La Du B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005, 46:1239-1247.
6. Mackness M.I., Arrol S., Abbott C., Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993, 104:129-135.
7. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998, 101:1581-1590.
8. Aviram M., Billecke S., Sorenson R., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998, 18:1617-1624.
9. Rosenblat M., Vaya J., Shih D., Aviram M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 2005, 179:69-77.
10. Brewer H.B. Clinical review: the evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab 2011, 96:1246-1257.
11. Rosenson R.S., Brewer H.B., Chapman M.J., et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011, 57:392-410.
12. Brown W.V., Brewer H.B., Rader D.J., Schaefer E.J. HDL as a treatment target. J Clin Lipidol 2010, 4:5-16.
13. Brewer H.B. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Curr Cardiol Rep 2007, 9:486-492.
14. Rosenson R.S. Functional assessment of HDL: moving beyond static measures for risk assessment. Cardiovasc Drugs Ther 2010, 24:71-75.
15. Kontush A., Chapman M.J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 2010, 21:312-318.
16. Kontush A., Guerin M., Chapman M.J. Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med 2008, 5:329-336.
17. Kontush A., Chapman M.J. Antiatherogenic small, dense HDL-guardian angel of the arterial wall?. Nat Clin Pract Cardiovasc Med 2006, 3:144-153.
18. Navab M., Reddy S.T., Van Lenten B.J., Fogelman A.M. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011, 8:222-232.
19. Corsetti J.P., Gansevoort R.T., Sparks C.E., Dullaart R.P. Inflammation reduces HDL protection against primary cardiac risk. Eur J Clin Invest 2010, 40:483-489.
20. Haase C.L., Tybjaerg-Hansen A., Qayyum A.A., Schou J., Nordestgaard B.G., Frikke-Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab 2012, 97:E248-E256.
21. Navab M., Reddy S.T., Van Lenten B.J., Anantharamaiah G.M., Fogelman A.M. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009, 50:S145-S149.
22. Kalantar-Zadeh K., Kopple J.D., Kamranpour N., Fogelman A.M., Navab M. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007, 72:1149-1156.
23. Davidson W.S., Silva R.A., Chantepie S., Lagor W.R., Chapman M.J., Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009, 29:870-876.
24. 3, and other lipoproteins in Gofman's Livermore Cohort. Atherosclerosis 2011, 214:196-202.
25. Ridker P.M., Genest J., Boekholdt S.M., et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010, 376(9738):333-339.
26. Blanche P.J., Gong E.L., Forte T.M., Nichols A.V. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981, 665:408-419.
27. Krauss R.M. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol 2011, 21:305-311.
28. Kontush A., Chapman M.J. Why is HDL functionally deficient in type 2 diabetes?. Curr Diab Rep 2008, 8:51-59.
29. Bergmeier C., Siekmeier R., Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem 2004, 50:2309-2315.
30. Besler C., Heinrich K., Rohrer L., et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011, 121:2693-2708.
31. Gugliucci A., Schulze J., Kinugasa E., Ogata H., Kimura S. The free fraction of paraoxonase 1 is not increased in patients with end stage renal disease undergoing hemodialysis. Clin Chim Acta 2009, 402:209-210.
32. Khersonsky O., Tawfik D.S. The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J Biol Chem 2006, 281:7649-7656.
33. Deakin S.P., James R.W. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci 2004, 107:435-447.
34. Sorenson R.C., Bisgaier C.L., Aviram M., Hsu C., Billecke S., La Du B.N. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999, 19:2214-2225.
35. Gaidukov L., Rosenblat M., Aviram M., Tawfik D.S. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res 2006, 47:2492-2502.
36. Richter R.J., Jarvik G.P., Furlong C.E. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet 2008, 1:147-152.
37. Costa L.G., Cole T.B., Jarvik G.P., Furlong C.E. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003, 54:371-392.
38. Mirdamadi H.Z., Sztanek F., Derdak Z., Seres I., Harangi M., Paragh G. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. Br J Clin Pharmacol 2008, 66:366-373.
39. Jakubowski H. The role of paraoxonase 1 in the detoxification of homocysteine thiolactone. Adv Exp Med Biol 2010, 660:113-127.
40. Perla-Kaján J., Jakubowski H. Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J 2010, 24:931-936.
41. Heinecke J.W. The HDL, proteome: a marker-and perhaps mediator-of coronary artery disease. J Lipid Res 2009, 50:S167-S171.
42. Toledo-Ibelles P., García-Sánchez C., Avila-Vazzini N., et al. Enzymatic assessment of cholesterol on electrophoresis gels for estimating HDL size distribution and plasma concentrations of HDL subclasses. J Lipid Res 2010, 51:1610-1617.
43. Garcia-Sanchez C., Torres-Tamayo M. Juarez-Meavepena, et al. Lipid plasma concentrations of HDL subclasses determined by enzymatic staining on polyacrylamide electrophoresis gels in children with metabolic syndrome. Clin Chim Acta 2011, 412:292-298.
44. Yamashita S., Matsuzawa Y. Where are we with probucol: a new life for an old drug?. Atherosclerosis 2009, 207(1):16-23.
45. Tardif J.C., Cote G., Lesperance J., et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997, 337:365-732.
46. Yamashita S., Hbujo H., Arai H., et al. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2008, 15(6):292-303.
47. Jensen M.K., Rimm E.B., Furtado J.D., Sacks F.M. Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J Am Heart Assoc 2012, 1:e000232. 10.1161/JAHA.111.000232.